Fibroblast Activation Protein α

Handbook of Proteolytic Enzymes

Volumn 3, Issue , 2013, Pages 3395-3401

  Gorrell, Mark D ^a   Park, John E ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884875512     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-382219-2.00750-X     Document Type: Chapter

References (61)

1. Rettig W.J., Garin-Chesa P., Beresford H.R., Oettgen H.F., Melamed M.R., Old L.J. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl. Acad. Sci. USA 1988, 85(9):3110-3114.
2. Rettig W.J., Garin-Chesa P., Healey J.H., Su S.L., Ozer H.L., Schwab M., Albino A.P., Old L.J. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993, 53(14):3327-3335.
3. Rettig W.J., Su S.L., Fortunato S.R., Scanlan M.J., Raj B.K., Garin-Chesa P., Healey J.H., Old L.J. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int. J. Cancer 1994, 58(3):385-392.
4. Scanlan M.J., Raj B.K., Calvo B., Garin-Chesa P., Sanz-Moncasi M.P., Healey J.H., Old L.J., Rettig W.J. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA 1994, 91(12):5657-5661.
5. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 1990, 87(18):7235-7239.
6. Wang X.M., Yao T.-W., Nadvi N.A., Osborne B., McCaughan G.W., Gorrell M.D. Fibroblast activation protein and chronic liver disease. Front. Biosci. 2008, 13:3168-3180.
7. Wang X.M., Yu D.M.T., McCaughan G.W., Gorrell M.D. Fibroblast activation protein increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology 2005, 42(4):935-945.
8. Gorrell M.D., Gysbers V., McCaughan G.W. CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scandinavian J. Immunol. 2001, 54(9):249-264.
9. Lee K.N., Jackson K.W., Christiansen V.J., Lee C.S., Chun J.G., McKee P.A. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006, 107(4):1397-1404.
10. Monsky W.L., Lin C.Y., Aoyama A., Kelly T., Akiyama S.K., Mueller S.C., Chen W.T. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 1994, 54(21):5702-5710.
11. Pineiro-Sanchez M.L., Goldstein L.A., Dodt J., Howard L., Yeh Y., Chen W.T. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J. Biol. Chem. 1997, 272(12):7595-7601.
12. Brown D.D., Wang Z., Furlow J.D., Kanamori A., Schwartzman R.A., Remo B.F., Pinder A. The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis. Proc. Natl. Acad. Sci. USA 1996, 93(5):1924-1929.
13. Park J.E., Lenter M.C., Zimmermann R.N., Garin-Chesa P., Old L.J., Rettig W.J. Fibroblast activation protein: A dual-specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 1999, 274:36505-36512.
14. Christiansen V.J., Jackson K.W., Lee K.N., McKee P.A. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch. Biochem. Biophys. 2007, 457(2):177-186.
15. Keane F.M., Nadvi N.A., Yao T.-W., Gorrell M.D. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation proteinα. FEBS J. 2011, 278:1316-1332.
16. Ajami K., Abbott C.A., McCaughan G.W., Gorrell M.D. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim. Biophys. Acta, Gene Struct. Expression 2004, 1679(1):18-28.
17. Park J., Knott H.M., Nadvi N.A., Collyer C.A., Wang X.M., Church W.B., Gorrell M.D. Reversible inactivation of human dipeptidyl peptidases 8 and 9 by oxidation. The Open Enzyme Inhibition Journal 2008, 1:52-61.
18. Dubois V., Lambeir A.-M., Vandamme S., Matheeussen V., Guisez Y., ScharpÈ S., De Meester I. Dipeptidyl peptidase 9 (DPP9) from bovine testes: Identification and characterization as the short form by mass spectrometry. Biochim. Biophys. Acta, Proteins Proteomics 2010, 1804(4):781-788.
19. Levy M.T., McCaughan G.W., Abbott C.A., Park J.E., Cunningham A.M., Muller E., Rettig W.J., Gorrell M.D. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999, 29(6):1768-1778.
20. Aggarwal S., Brennen W.N., Kole T.P., Schneider E., Topaloglu O., Yates M., Cotter R.J., Denmeade S.R. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008, 47(3):1076-1086.
21. Lee K.N., Jackson K.W., Terzyan S., Christiansen V.J., McKee P.A. Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. Biochemistry 2009, 48(23):5149-5158.
22. Edosada C.Y., Quan C., Tran T., Pham V., Wiesmann C., Fairbrother W., Wolf B.B. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 2006, 580(6):1581-1586.
23. Huang C.-H., Suen C.-S., Lin C.-T., Chien C.-H., Lee H.-Y., Chung K.-M., Tsai T.-Y., Jiaang W.-T., Hwang M.-J., Chen X. Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J. Biochem. 2011, 149(6):685-692.
24. Sudmeier J.L., Zhou Y., Lai J.H., Maw H.H., Wu W., Bachovchin W.W. Autochelation in dipeptide boronic acids: pH-dependent structures and equilibria of Asp-boroPro and His-boroPro by NMR spectroscopy. J. Am. Chem. Soc. 2005, 127(22):8112-8119.
25. Santos A.M., Jung J., Aziz N., Kissil J.L., Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 2010, 119(12):3613-3626.
26. Tsai T.-Y., Yeh T.-K., Chen X., Hsu T., Jao Y.-C., Huang C.-H., Song J.-S., Huang Y.-C., Chien C.-H., Chiu J.-H., Yen S.-C., Tang H.-K., Chao Y.-S., Jiaang W.-T. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. J. Med. Chem. 2010, 53(18):6572-6583.
27. Thomas L., Eckhardt M., Langkopf E., Tadayyon M., Himmelsbach F., Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazo lin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 2008, 325(1):175-182.
28. Del Prato S., Barnett A.H., Huisman H., Neubacher D., Woerle H.J., Dugi K.A. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 2011, 13(3):258-267.
29. Aertgeerts K., Levin I., Shi L., Snell G.P., Jennings A., Prasad G.S., Zhang Y., Kraus M.L., Salakian S., Sridhar V., Wijnands R., Tennant M.G. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α. J. Biol. Chem. 2005, 280:19441-19444.
30. Meadows S.A., Edosada C.Y., Mayeda M., Tran T., Quan C., Raab H., Wiesmann C., Wolf B.B. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization. Biochemistry 2007, 46(15):4598-4605.
31. Niedermeyer J., Scanlan M.J., Garin-Chesa P., Daiber C., Fiebig H.H., Old L.J., Rettig W.J., Schnapp A. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int. J. Cancer 1997, 71(3):383-389.
32. Niedermeyer J., Kriz M., Hilberg F., Garin-Chesa P., Bamberger U., Lenter M.C., Park J., Viertel B., Puschner H., Mauz M., Rettig W.J., Schnapp A. Targeted disruption of mouse fibroblast activation protein. Mol. Cell. Biol. 2000, 20(3):1089-1094.
33. Niedermeyer J., Enenkel B., Park J.E., Lenter M., Rettig W.J., Damm K., Schnapp A. Mouse fibroblast-activation protein: Conserved Fap gene organization and biochemical function as a serine protease. Eur. J. Biochem. 1998, 254(3):650-654.
34. Sappino A.P., Masouye I., Saurat J.H., Gabbiani G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am. J. Pathol. 1990, 137(3):585-591.
35. Bauer S., Jendro M.C., Wadle A., Kleber S., Stenner F., Dinser R., Reich A., Faccin E., Godde S., Dinges H., Muller-Ladner U., Renner C. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res. Ther. 2006, 8(6):R171.
36. Milner J.M., Kevorkian L., Young D.A., Jones D., Wait R., Donell S.T., Barksby E., Patterson A.M., Middleton J., Cravatt B.F., Clark I.M., Rowan A.D., Cawston T.E. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Res. Ther. 2006, 8(1):R23.
37. Gao M.-Q., Kim B.G., Kang S., Choi Y.P., Park H., Kang K.S., Cho N.H. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J. Cell Sci. 2010, 123(20):3507-3514.
38. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., Gopinathan A., Tuveson D.A., Fearon D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation proteinα. Science 2010, 330(6005):827-830.
39. Pure E. The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Exp. Opin. Ther. Targets 2009, 13(8):967-973.
40. Welt S., Divgi C.R., Scott A.M., Garin-Chesa P., Finn R.D., Graham M., Carswell E.A., Cohen A., Larson S.M., Old L.J. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 1994, 12(6):1193-1203.
41. Levy M.T., McCaughan G.W., Marinos G., Gorrell M.D. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver Int. 2002, 22(2):93-101.
42. Acharya P.S., Zukas A., Chandan V., Katzenstein A.L., Pure E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum. Pathol. 2006, 37(3):352-360.
43. Ospelt C., Mertens J.C., Juengel A., Brentano F., Maciejewska-Rodriguez H., Huber L.C., Hemmatazad H., Wüest T., Knuth A., Gay R.E., Michel B.A., Gay S., Renner C., Bauer S. Inhibition of fibroblast activation protein and dipeptidyl peptidase IV increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2010, 62(5):1224-1235.
44. Brokopp C.E., Schoenauer R., Richards P., Bauer S., Lohmann C., Emmert M.Y., Weber B., Winnik S., Aikawa E., Graves K., Genoni M., Vogt P., Lüscher T.F., Renner C., Hoerstrup S.P., Matter C.M. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur. Heart J. 2011, 32(21):2713-2722.
45. Lee K.N., Jackson K.W., Christiansen V.J., Chung K.H., McKee P.A. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004, 103(10):3783-3788.
46. Henry L.R., Lee H.O., Lee J.S., Klein-Szanto A., Watts P., Ross E.A., Chen W.T., Cheng J.D. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 2007, 13(6):1736-1741.
47. Ostermann E., Garin-Chesa P., Heider K.H., Kalat M., Lamche H., Puri C., Kerjaschki D., Rettig W.J., Adolf G.R. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 2008, 14(14):4584-4592.
48. LeBeau A.M., Brennen W.N., Aggarwal S., Denmeade S.R. Targeting cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol. Cancer Ther. 2009, 8(5):1378-1386.
49. Goscinski M.A., Suo Z., Florenes V.A., Vlatkovic L., Nesland J.M., Giercksky K.-E. FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct. Pathol. 2008, 32(3):89-96.
50. Bhati R., Patterson C., Livasy C.A., Fan C., Ketelsen D., Hu Z., Reynolds E., Tanner C., Moore D.T., Gabrielli F., Perou C.M., Klauber-DeMore N. Molecular characterization of human breast tumor vascular cells. Am. J. Pathol. 2008, 172(5):1381-1390.
51. Wen Y., Wang C., Ma T., Li Z., Zhou L., Mu B., Leng F., Shi H., Li Y., Wei Y. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 2010, 101(11):2325-2332.
52. Cheng J.D., Dunbrack R.L., Valianou M., Rogatko A., Alpaugh R.K., Weiner L.M. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002, 62(16):4767-4772.
53. Abbott C.A., Yu D.M.T., Woollatt E., Sutherland G.R., McCaughan G.W., Gorrell M.D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 2000, 267(20):6140-6150.
54. Yu D.M.T., Ajami K., Gall M.G., Park J., Lee C.S., Evans K., McLaughlin E.A., Pitman M.R., Abbott C.A., McCaughan G.W., Gorrell M.D. The in vivo expression of dipeptidyl peptidases 8 and 9. J. Histochem. Cytochem. 2009, 57(11):1025-1040.
55. Chen T., Ajami K., McCaughan G.W., Gai W.-P., Gorrell M.D., Abbott C.A. Molecular characterization of a novel dipeptidyl peptidase like 2 short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. Biochim. Biophys. Acta 2005, 1764(1):33-43.
56. McNicholas K., Chen T., Abbott C. Dipeptidyl peptidase (DP) 6 and DP10: novel brain proteins implicated in human health and disease. Clin. Chem. Lab. Med. 2009, 47(3):262.
57. Yokotani N., Doi K., Wenthold R.J., Wada K. Non-conservation of a catalytic residue in a dipeptidyl aminopeptidase IV-related protein encoded by a gene on human chromosome 7. Hum. Mol. Gen. 1993, 2(7):1037-1039.
58. Ajami K., Pitman M.R., Wilson C.H., Park J., Menz R.I., Starr A.E., Cox J.H., Abbott C.A., Overall C.M., Gorrell M.D. Stromal cell-derived factors 1 alpha and 1 beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett. 2008, 582(5):819-825.
59. Bjelke J.R., Christensen J., Nielsen P.F., Branner S., Kanstrup A.B., Wagtmann N., Rasmussen H.B. Dipeptidyl peptidase 8 and 9 specificity and molecular characterization compared to dipeptidyl peptidase IV. Biochem. J. 2006, 396(2):391-399.
60. Lankas G., Leiting B., Roy R., Eiermann G., Beconi M., Biftu T., Chan C., Edmondson S., Feeney W., He H., Ippolito D., Kim D., Lyons K., Ok H., Patel R., Petrov A., Pryor K., Qian X., Reigle L., Woods A., Wu J., Zaller D., Zhang X., Zhu L., Weber A., Thornberry N. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54(10):2988-2994.
61. Yu D.M.T., Yao T.-W., Chowdhury S., Nadvi N.A., Osborne B., Church W.B., McCaughan G.W., Gorrell M.D. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J. 2010, 277:1126-1144.